Clinical application of dabigatran assisted surgery in the treatment of hypertrophic cardiomyopathy with atrial fibrillation
Objective To observe the clinical effect of dabigatran in the treatment of hypertrophic cardiomyopathy(HCM)with atrial fibrillation(AF).Methods 121 patients with HCM combined with AF were selected and randomly divided into the contral group and observation group using a digital table method.Both groups underwent radiofrequency ablation treatment,while the control group had 60 patients who were received conventional anticoagulant therapy as an adjuvant surgery.The observation group had 61 patients who were received dabigatran as an adjuvant surgery.The changes in platelet activity and coagulation function before and after treatment were compared between the two groups,as well as the occurrence of cardiovascular adverse events and drug-related side reactions during the follow-up period.Results After treatment,the observation group's β-TG,granular membrane protein CD62P,CD63 were lower than those of control group,while activated partial thromboplastin time(APTT),prothrombin time(PT),thrombin time(TT)were higher than those of control group(P<0.05);during the follow-up period,the incidence of cardiovascular adverse events and adverse reactions in observation group were lower than those in control group,with statistically significant differences(P<0.05).Conclusion Dabigatran assisted radiofrequency ablation can effectively inhibit platelet activity and improve coagulation function in patients with HCM and AF,and has positive significance in reducing of cardiovascular adverse events and drug adverse reactions.
NETL
NSTL
万方数据
